Use and Underuse of Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: Old and New Paradigms

Ron Pisters; Cees B de Vos; Robby Nieuwlaat; Harry J. G. M Crijns

doi:10.1055/s-0029-1241048

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2009; 35(6): 554-559
DOI: 10.1055/s-0029-1241048

Use and Underuse of Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: Old and New Paradigms

Ron Pisters¹ , Cees B. de Vos¹ , Robby Nieuwlaat¹ , Harry J. G. M Crijns¹

¹Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands

Abstract

ABSTRACT

Atrial fibrillation (AF) is the most common sustained arrhythmia of the Western world. The increased ischemic stroke risk of the AF patient is one of the most important clinical issues to manage. Despite the well-known benefit of oral anticoagulation in high-risk AF patients, these drugs are widely underused in daily practice all over the world. We describe old and new paradigms of the use of oral anticoagulation. In the future, increased comprehensibility of stroke risk scores, development of a validated clinical bleed risk score, and new patient and physician user-friendly antithrombotic medication may contribute to improved adequate use of oral anticoagulation in AF patients.

KEYWORDS

Atrial fibrillation - oral anticoagulation - stroke prevention

Full Text

References

REFERENCES

1 Wolf P A, Abbott R D, Kannel W B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22(8) 983-988
2 Hart R G, Pearce L A, Rothbart R M, McAnulty J H, Asinger R W, Halperin J L. Stroke Prevention in Atrial Fibrillation Investigators . Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Am Coll Cardiol. 2000; 35(1) 183-187
3 Nieuwlaat R, Dinh T, Olsson S B Euro Heart Survey Investigators et al. Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?. Eur Heart J. 2008; 29(7) 915-922
4 Lip G Y. Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis. Thromb Haemost. 2008; 100(1) 11-13
5 Fuster V, Rydén L E, Cannom D S European Heart Rhythm Association et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006; 48(4) 854-906
6 Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994; 154(13) 1449-1457
7 Hart R G, Pearce L A, Aguilar M I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12) 857-867
8 Waldo A L, Becker R C, Tapson V F, Colgan K J. NABOR Steering Committee . Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol. 2005; 46(9) 1729-1736
9 Nieuwlaat R, Capucci A, Lip G Y Euro Heart Survey Investigators et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006; 27(24) 3018-3026
10 Dinh T, Nieuwlaat R, Tieleman R G et al.. Antithrombotic drug prescription in atrial fibrillation and its rationale among general practitioners, internists and cardiologists in The Netherlands—The EXAMINE-AF study. A questionnaire survey. Int J Clin Pract. 2007; 61(1) 24-31
11 The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators . The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990; 323(22) 1505-1511
12 Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991; 84(2) 527-539
13 Petersen P, Boysen G, Godtfredsen J, Andersen E D, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989; 1(8631) 175-179
14 Connolly S J, Laupacis A, Gent M, Roberts R S, Cairns J A, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol. 1991; 18(2) 349-355
15 Ezekowitz M D, Bridgers S L, James K E Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992; 327(20) 1406-1412
16 EAFT (European Atrial Fibrillation Trial) Study Group . Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993; 342(8882) 1255-1262
17 Stroke Risk in Atrial Fibrillation Working Group . Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008; 39(6) 1901-1910
18 Nieuwlaat R. Management of Atrial Fibrillation in Europe [dissertation]. Maastricht, the Netherlands; Maastricht University 2007
19 Hart R G, Pearce L A, McBride R, Rothbart R M, Asinger R W. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators . Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. Stroke. 1999; 30(6) 1223-1229
20 Gage B F, Waterman A D, Shannon W, Boechler M, Rich M W, Radford M J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285(22) 2864-2870
21 Wang T J, Massaro J M, Levy D et al.. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003; 290(8) 1049-1056
22 Fang M C, Go A S, Chang Y, Borowsky L, Pomernacki N K, Singer D E. ATRIA Study Group . Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2008; 51(8) 810-815
23 Hohnloser S H, Pajitnev D, Pogue J ACTIVE W Investigators et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol. 2007; 50(22) 2156-2161
24 Van Gelder I C, Hagens V E, Bosker H A Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002; 347(23) 1834-1840
25 Wyse D G, Waldo A L, DiMarco J P Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347(23) 1825-1833
26 Poli D, Antonucci E, Marcucci R et al.. Risk of bleeding in very old atrial fibrillation patients on warfarin: relationship with ageing and CHADS2 score. Thromb Res. 2007; 121(3) 347-352
27 Gage B F, Yan Y, Milligan P E et al.. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006; 151(3) 713-719
28 Fang M C, Go A S, Chang Y et al.. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007; 120(8) 700-705
29 Chimowitz M I, Lynn M J, Howlett-Smith H Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005; 352(13) 1305-1316
30 Go A S, Hylek E M, Chang Y et al.. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?. JAMA. 2003; 290(20) 2685-2692
31 Hylek E M, Go A S, Chang Y et al.. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003; 349(11) 1019-1026
32 Fang M C, Chang Y, Hylek E M et al.. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004; 141(10) 745-752
33 Perry Jr H M, Davis B R, Price T R et al.. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 2000; 284(4) 465-471
34 Hylek E M, Evans-Molina C, Shea C, Henault L E, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007; 115(21) 2689-2696
35 Hylek E M, Singer D E. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994; 120(11) 897-902
36 Hylek E M, Skates S J, Sheehan M A, Singer D E. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996; 335(8) 540-546
37 Shireman T I, Howard P A, Kresowik T F, Ellerbeck E F. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke. 2004; 35(10) 2362-2367
38 Hart R G, Benavente O, Pearce L A. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis. 1999; 9(4) 215-217
39 Beyth R J, Quinn L M, Landefeld C S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998; 105(2) 91-99
40 Kuijer P M, Hutten B A, Prins M H, Büller H R. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med. 1999; 159(5) 457-460
41 Kearon C, Ginsberg J S, Kovacs M J Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003; 349(7) 631-639
42 Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999; 159(7) 677-685
43 Garwood C L, Corbett T L. Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls. Ann Pharmacother. 2008; 42(4) 523-532
44 Mant J, Hobbs F D, Fletcher K BAFTA investigators et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007; 370(9586) 493-503
45 van Walraven C, Hart R G, Connolly S et al.. Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation: The Atrial Fibrillation Investigators. Stroke. 2009; 40(4) 1410-1416
46 Marini C, De Santis F, Sacco S et al.. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005; 36(6) 1115-1119
47 Nieuwlaat R, Olsson S B, Lip G Y Euro Heart Survey Investigators et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. Am Heart J. 2007; 153(6) 1006-1012
48 Pisters R, Knottnerus I, Crijns H J et al.. Antithrombotic guideline adherence in atrial fibrillation patients admitted with stroke. Do we use our safety-belt?. Paper presented at: Annual meeting of the European Society of Cardiology September 2, 2007 Vienna, Austria;
49 Gladstone D J, Bui E, Fang J et al.. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009; 40(1) 235-240

Ron Pisters

Department of Cardiology, Maastricht University Medical Centre

PO Box 5800, 6202 AZ Maastricht, The Netherlands

Email: r.pisters@mumc.nl